Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. insiders are currently net sellers of ITCI stock, showing bearish sentiment over the past 90 days. Total sales of $209.3M outpace purchases of $50.0M, creating a net outflow of $159.3M. However, 72% of these sales are pre-scheduled 10b5-1 plan transactions.

Intra-Cellular Therapies, Inc. has 20 active insiders who have filed SEC Form 4 transactions in the past 90 days. Sharon Mates (Executive) leads with 162 transactions totaling $84.1M. Lawrence J. Hineline (Executive) follows with 141 transactions worth $45.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Intra-Cellular Therapies, Inc.'s current score of 19/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Dec 5, 2024, when Mates Sharon (Executive) disposed of 51,697 shares at $0.00 per share for $0. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, ITCI insider trading sentiment is currently bearish with an Alignment Score of 19/100. The negative net flow of $159.3M shows more selling than buying. However, 72% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Intra-Cellular Therapies, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ITCI, we track all Form 4 filings—currently showing 912 transactions from 20 insiders over 90 days.

A 10b5-1 plan allows Intra-Cellular Therapies, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ITCI, approximately 72% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Intra-Cellular Therapies, Inc. (ITCI) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 20 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Intra-Cellular Therapies, Inc.'s current score of 19/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $50.0M in purchases versus $209.3M in sales over 90 days, resulting in a net flow of -$159.3M.

SEC Form 4 filings are mandatory reports that Intra-Cellular Therapies, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ITCI, the most common type is "M" with 28 occurrences. The most recent Form 4 was filed on Dec 5, 2024 by Mates Sharon.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Intra-Cellular Therapies, Inc., approximately 72% of recent transactions are executed under 10b5-1 plans, while 28% appear to be discretionary trades. This high percentage suggests selling activity may be routine diversification.